We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
In the latest market close, Medpace (MEDP - Free Report) reached $347.91, with a +0.93% movement compared to the previous day. The stock outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.97%, and the Nasdaq, a tech-heavy index, added 0.33%.
The provider of outsourced clinical development services's stock has dropped by 0.07% in the past month, exceeding the Medical sector's loss of 3.79% and lagging the S&P 500's gain of 5.36%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on October 21, 2024. It is anticipated that the company will report an EPS of $2.78, marking a 25.23% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $540.49 million, reflecting a 9.74% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $11.64 per share and revenue of $2.13 billion, which would represent changes of +31.08% and +13.03%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.11% downward. Medpace presently features a Zacks Rank of #4 (Sell).
Digging into valuation, Medpace currently has a Forward P/E ratio of 29.61. This expresses a premium compared to the average Forward P/E of 20.24 of its industry.
Investors should also note that MEDP has a PEG ratio of 1.79 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.78.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 176, positioning it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medpace (MEDP) Rises Higher Than Market: Key Facts
In the latest market close, Medpace (MEDP - Free Report) reached $347.91, with a +0.93% movement compared to the previous day. The stock outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.97%, and the Nasdaq, a tech-heavy index, added 0.33%.
The provider of outsourced clinical development services's stock has dropped by 0.07% in the past month, exceeding the Medical sector's loss of 3.79% and lagging the S&P 500's gain of 5.36%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on October 21, 2024. It is anticipated that the company will report an EPS of $2.78, marking a 25.23% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $540.49 million, reflecting a 9.74% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $11.64 per share and revenue of $2.13 billion, which would represent changes of +31.08% and +13.03%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Medpace. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.11% downward. Medpace presently features a Zacks Rank of #4 (Sell).
Digging into valuation, Medpace currently has a Forward P/E ratio of 29.61. This expresses a premium compared to the average Forward P/E of 20.24 of its industry.
Investors should also note that MEDP has a PEG ratio of 1.79 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.78.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 176, positioning it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.